Eli Lilly and Company Stock Reverses Sharply After Beating Earnings Estimates

Eli Lilly and Company stock presents a sharp contrast: a strong Q2 earnings beat and raised 2026 guidance on one side, and a daily chart showing the stock giving back most gains on the other. Understanding why these two pictures disagree is key to reading LLY right now.

Key takeaways

• Eli Lilly reported better-than-expected Q2 2026 results, driven by injectable GLP-1 products and the oral pill Foundayo.
• Management raised full-year sales guidance, with the company now treating nearly 10% of the US obesity population with GLP-1 therapies.
• LLY opened at 1177.50, spiked to 1215.94, then reversed to close at 1148.61, forming a classic rejection candle on the daily chart.
• The daily MACD shows a bearish crossover at -2.07 against a signal of 7.37, while RSI14 sits at a neutral 47.47.
• Price must reclaim the daily pivot at 1167.95 and EMA20 at 1164.18 to revive the bullish case.

Eli Lilly and Company Stock: Daily Structure Shows a Rejection, Not a Breakout

The daily chart shows a classic rejection, not a breakout. LLY opened at 1177.50, spiked to an intraday high of 1215.94, then reversed sharply to close at 1148.61, near the session low of 1139.29.

… Continue reading the full article at the original source below.